American Association for Cancer Research Inaugurates New Leadership at 2019 Annual Meeting
Dr. Elaine R. Mardis inaugurated as President ATLANTA – The American Association for Cancer Research (AACR) welcomes Elaine R....
Search/Filter
Loading...
Data From Two KEYNOTE Trials Show Pembrolizumab Benefited Patients With Advanced Small Cell Lung Cancer
ATLANTA – The anti-PD-1 monoclonal antibody pembrolizumab (Keytruda) showed promising antitumor activity with durable responses in patients with pretreated,...
Umbralisib Shows Early Promise for Patients with Marginal Zone Lymphoma
ATLANTA – The investigational therapeutic umbralisib, which targets the molecule PI3K-delta, was well tolerated and highly active in patients...
Cancer Preventive Vaccine Showed Promising Results in Preclinical Model of Lynch Syndrome
“ATLANTA – Vaccination with as few as four tumor antigens generated antigen-specific responses, reduced intestinal tumors, and improved survival...
Gilteritinib Improved Survival for Patients With Acute Myeloid Leukemia
“ATLANTA – Treatment with the FLT3-targeted therapeutic gilteritinib (Xospata) improved survival for patients with relapsed or refractory acute myeloid...
Emil J Freireich Honored With AACR Award for Lifetime Achievement in Cancer Research
PHILADELPHIA – The American Association for Cancer Research (AACR) recognized Emil J Freireich, MD, FAACR, with the 2019 AACR...
Excess Body Weight Before age 50 is Associated With Higher Risk of Dying From Pancreatic Cancer
ATLANTA – Excess weight before age 50 may be more strongly associated with pancreatic cancer mortality risk than excess...
Immune Checkpoint Inhibitor Combination Efficacious For Patients With High-grade Neuroendocrine Carcinoma
ATLANTA – A combination of the anti-CTLA-4 immunotherapeutic ipilimumab (Yervoy) and the anti-PD-1 immunotherapeutic nivolumab (Opdivo) showed clinical benefit...
Adding the MET Inhibitor Savolitinib to Osimertinib was Beneficial for Certain Pretreated Lung Cancer Patients in TATTON Trial
ATLANTA – Adding the investigational MET inhibitor savolitinib to the EGFR inhibitor osimertinib (Tagrisso) yielded clinical responses in patients...
Mesothelin-targeted CAR T-cell Therapy Safe, Shows Early Promise in Patients With Advanced Solid Tumors
ATLANTA – A chimeric antigen receptor (CAR) T-cell therapy that targets the protein mesothelin showed no evidence of major...